(Q39822812)

14 September 2017

1 reference

title

Cytotoxic agents for use in dermatology. I. (English)

1 reference

14 September 2017

0 references

McDonald CJ

1

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 May 1985

1 reference

Journal of the American Academy of Dermatology

14 September 2017

published in

1 reference

14 September 2017

volume

12

1 reference

14 September 2017

issue

5 Pt 1

1 reference

14 September 2017

page(s)

753-775

1 reference

Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Skin Tumours in Immunosuppressed Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

1 reference

7 January 2021

Defective DNA endonuclease activity on anthramycin treated DNA in xeroderma pigmentosum and mouse melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Frequent low doses of intravenous mechlorethamine for late-stage mycosis fungoides lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Mechlorethamine hydrochloride solutions and ointment. Prolonged stability and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Topical mustine hydrochloride and psoriasis: a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Effects of Topical Mechlorethamine on Skin Lesions of Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Treatment of Pemphigus Vulgaris With Methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Polymyositis and Dermatomyositis: Combined Methotrexate and Corticosteroid Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Methotrexate guidelines--revised

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Recent advances in the chemotherapy of metastatic osteogenic sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Liver disease in psoriatics--An effect of methotrexate therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Beneficial Effects of Triacetyl Azauridine in Psoriasis and Mycosis Fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Clinical studies with systemic administration of antimetabolites of pyrimidine nucleosides in viral infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

A Trial of Topical Acyclovir in Genital Herpes Simplex Virus Infections

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Chemotherapy of systemic mycoses (first of two parts).

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Azaribine for Mycosis Fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Treatment Of Herpes Keratitis With 5-Iodo-2-Deoxyuridine (Idu)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Failure of high dose 5-iodo-2'-deoxyuridine in the therapy of herpes simplex virus encephalitis. Evidence of unacceptable toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Nucleoside analogs in the treatment of nonneoplastic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

The pharmacological and immunological basis for the use of immunosuppressive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

The immunosuppressive mechanism of azathioprine. I. In vitro effect on lymphocyte function in the baboon

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Immunosuppression with azathioprine, prednisone, and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Acyclovir comes of age

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Treatment of psoriasis with mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Treatment of psoriatic arthritis with 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Azathioprine therapy of ?autoimmune? diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Azathioprine for pemphigus and pemphigoid--a 4 year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Prognostic indices in lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Immunosuppressive agents in corticosteroid-refractory childhood dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Immunosuppressive and corticosteroid therapy of polyarteritis nodosa

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

In vitro susceptibility of varicella-zoster virus to acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Growth Inhibition by Acycloguanosine of Herpesviruses Isolated from Human Infections

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

The in vitro activity of Acyclovir and related compounds against cytomegalovirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Acyclovir inhibition of Epstein-Barr virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Novel substrate of adenosine deaminase

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Human pharmacokinetics of acyclovir (an antiviral agent) following rapid intravenous injection

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Acyclovir kinetics after intravenous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Latent Herpes Simplex Virus Infections in Sensory Ganglia of Hairless Mice Prevented by Acycloguanosine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Efficacy of acycloguanosine (Wellcome 248U) against herpes-simplex corneal ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Randomised double-blind trial of acyclovir and idoxuridine in dendritic corneal ulceration

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Comparative trial of acyclovir and adenine arabinoside in the treatment of herpes simplex corneal ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Acyclovir prophylaxis of herpes-simplex-virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Acyclovir for chronic mucocutaneous herpes simplex virus infection in immunosuppressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Treatment of eczema herpeticum with acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Transient renal impairment during intravenous acyclovir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Parenteral acyclovir therapy for herpesvirus infections in man

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Treatment of Kaposi's sarcoma with vinblastine

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

Hydroxyurea: induction of breaks in template strands of replicating DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2885%2970097-7

7 January 2021

10.1016/S0190-9622(85)70097-7

Identifiers

DOI

0 references

1 reference